日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Biomarker Discovery for Early Detection of Pancreatic Ductal Adenocarcinoma (PDAC) Using Multiplex Proteomics Technology

利用多重蛋白质组学技术发现用于胰腺导管腺癌(PDAC)早期检测的生物标志物

Athanasiou, Alcibiade; Kureshi, Natasha; Wittig, Anja; Sterner, Maria; Huber, Ramy; Palma, Norma A; King, Thomas; Schiess, Ralph

Evaluation of Proclarix in the diagnostic work-up of prostate cancer

评估普罗克莱瑞克斯在前列腺癌诊断流程中的应用

Kaufmann, Basil; Fischer, Sharon; Athanasiou, Alcibiade; Lautenbach, Noémie; Wittig, Anja; Bieri, Uwe; Schmid, Florian A; von Stauffenberg, Franz; Scherer, Thomas; Eberli, Daniel; Gorin, Michael A; Schiess, Ralph; Poyet, Cédric

A novel serum biomarker quintet reveals added prognostic value when combined with standard clinical parameters in prostate cancer patients by predicting biochemical recurrence and adverse pathology.

一种新型血清生物标志物五重奏与前列腺癌患者的标准临床参数相结合,通过预测生化复发和不良病理,显示出额外的预后价值

Athanasiou Alcibiade, Tennstedt Pierre, Wittig Anja, Huber Ramy, Straub Oliver, Schiess Ralph, Steuber Thomas

Analytical performance of thrombospondin-1 and cathepsin D immunoassays part of a novel CE-IVD marked test as an aid in the diagnosis of prostate cancer.

血小板反应蛋白-1和组织蛋白酶D免疫测定的分析性能,作为新型CE-IVD标记测试的一部分,用于辅助诊断前列腺癌

Macagno Annalisa, Athanasiou Alcibiade, Wittig Anja, Huber Ramy, Weber Stephan, Keller Thomas, Rhiel Martin, Golding Bruno, Schiess Ralph

Thrombospondin 1 and cathepsin D improve prostate cancer diagnosis by avoiding potentially unnecessary prostate biopsies

血小板反应蛋白1和组织蛋白酶D可通过避免可能不必要的前列腺活检来改善前列腺癌的诊断。

Steuber, Thomas; Tennstedt, Pierre; Macagno, Annalisa; Athanasiou, Alcibiade; Wittig, Anja; Huber, Ramy; Golding, Bruno; Schiess, Ralph; Gillessen, Silke